NEWS
Terns Pharmaceuticals Highlights New Preclinical Data Supporting TERN-501 in Combination with a GLP-1R Agonist for Obesity at the ADA’s 84th Annual Scientific Sessions and Upcoming Conference Participation
Terns Pharmaceuticals announced new preclinical data supporting their compound TERN-501 in combination with a GLP-1 receptor agonist for treating obesity. The data was presented at the ADA’s 84th Annual Scientific Sessions. TERN-501, a highly selective THR-β receptor agonist, was shown to enhance weight loss efficacy when used with a GLP-1 receptor agonist, specifically semaglutide, in obese mice. This combination resulted in increased fat mass loss and preserved lean mass, potentially overcoming metabolic adaptation that limits the effectiveness of GLP-1 therapies alone. The results suggest TERN-501 could be a promising adjunct to GLP-1 therapies for obesity and other metabolic disorders. Additionally, Terns will participate in the Piper Sandler Virtual Obesity Day on June 26, 2024.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1095Followers
69Following
7575Visitors
Follow
Paul Anthony : very helpful thanks
